Alimera Sciences (Alimera Sciences) 12-1 Month Momentum % : 93.50% (As of Apr. 29, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-29), Alimera Sciences's 12-1 Month Momentum % is 93.50%.

The industry rank for Alimera Sciences's 12-1 Month Momentum % or its related term are showing as below:

ALIM's 12-1 Month Momentum % is ranked better than
92.63% of 1112 companies
in the Drug Manufacturers industry
Industry Median: -5.73 vs ALIM: 93.50

Competitive Comparison of Alimera Sciences's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alimera Sciences's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's 12-1 Month Momentum % falls into.

Alimera Sciences (NAS:ALIM) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alimera Sciences (NAS:ALIM) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Alimera Sciences 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (Alimera Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Executives

Margaret Pax	director	6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko	director	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont	director	51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers	other: Chairman Emeritus	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan	director	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman	10 percent owner	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076